Phathom Pharmaceuticals Inc. Common Stock (PHAT)
Stock · NASDAQ · Health Care
$6.92as of 10/16/2026
Price chart
Active signals
PHAT Signal Track Record
How signals performed across all stocks →What PHAT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | +0.7% | 51% | July 30, 2026 |
| Bollinger Band Breakout | 21 | +1.1% | 52% | July 8, 2026 |
| Bollinger Band Breakdown | 20 | -0.9% | 50% | September 10, 2026 |
| 200-Day Moving Average TouchActive now | 11 | -3.6% | 27% | July 10, 2026 |
| Any 20-session window (baseline) | -0.2% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PHAT
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical t…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 371
- Website
- www.phathompharma.com/
Fundamentals
- 1-day range
- $6.98$7.57
- Market cap
- $678.76M
- P/E (trailing)
- —
- P/E (forward)
- 6.53
- EPS (trailing)
- $-1.27
- Dividend yield
- —
- Beta
- 0.57
- Avg. volume
- 1.39M
How Phathom Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
11 analyst ratings
Phathom Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PHATPhathom Pharmaceuticals Inc. Common Stock$6.92▼ 7.73%Market cap $678.76MP/E —$6.52$18.31
- NGNENeurogene Inc. Common Stock$23.25▼ 2.92%Market cap $680.52MP/E —$15.93$43.66
- HELPCybin Inc. Common Stock$10.55▼ 4.52%Market cap $688.02MP/E —$5.3$20.88
- EVOEvotec SE American Depositary Shares$1.38▼ 2.82%Market cap $693.72MP/E —$2.41$7.3
- FBIOPFortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock$16.67▼ 1.30%Market cap $662.39MP/E 0.58$1.88$4.53
- IRWDIronwood Pharmaceuticals Inc. Class A Common Stock$3.5▼ 7.16%Market cap $701.25MP/E 4.68$1.41$5.78
- IMMXImmix Biopharma Inc. Common Stock$7.98▼ 8.06%Market cap $702.09MP/E —$2.31$15.1
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PHAT Phathom Pharmaceuticals Inc. Common Stock | $678.76M | — | $6.92 | ▼ 7.73% | $6.52$18.31 |
| NGNE Neurogene Inc. Common Stock | $680.52M | — | $23.25 | ▼ 2.92% | $15.93$43.66 |
| HELP Cybin Inc. Common Stock | $688.02M | — | $10.55 | ▼ 4.52% | $5.3$20.88 |
| EVO Evotec SE American Depositary Shares | $693.72M | — | $1.38 | ▼ 2.82% | $2.41$7.3 |
| FBIOP Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock | $662.39M | 0.58 | $16.67 | ▼ 1.30% | $1.88$4.53 |
| IRWD Ironwood Pharmaceuticals Inc. Class A Common Stock | $701.25M | 4.68 | $3.5 | ▼ 7.16% | $1.41$5.78 |
| IMMX Immix Biopharma Inc. Common Stock | $702.09M | — | $7.98 | ▼ 8.06% | $2.31$15.1 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Phathom Pharmaceuticals To Present New Cost-Effectiveness Data For VOQUEZNA At The American College Of Gastroenterology Meeting, October 9-14;benzinga · 10/12/2026
- Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific MeetingYahoo · 10/8/2026
- Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERDYahoo · 9/29/2026
- Phathom Pharmaceuticals Initiates Registrational Phase 3 Study Of VOQUEZNA For As-Needed Treatment Of Non-Erosive GERDBenzinga · 9/29/2026
Insider Activity
Insider Actions →- Narula Sanjeev · October 6, 2026 · Tax Withholding13.5K @ $6.78
- Breedlove Robert Charles · September 3, 2026 · Tax Withholding460 @ $9.05
- Breedlove Robert Charles · July 14, 2026 · Tax Withholding1.6K @ $11.04
- Parikh Asit · May 22, 2026 · Gift28.0K
- Parikh Asit · May 20, 2026 · Disposition17.5K
- Parikh Asit · May 20, 2026 · Option Exercise17.5K @ $4.95
- Parikh Asit · May 19, 2026 · Grant24.1K
- Stenhouse Mark · May 19, 2026 · Grant24.1K
- Schroeder Theodore R · May 19, 2026 · Grant24.1K
- James N. Topper · May 19, 2026 · Grant24.1K
- KARBE FRANK · May 19, 2026 · Grant24.1K
- COLA MICHAEL F · May 19, 2026 · Grant24.1K
- FIELDS HEIDI · May 19, 2026 · Grant24.1K
Institutional Ownership
March 31, 2026
- Total shares held
- 68.63M
- Total value held
- $742.04M
- Institutional holders
- 169
- Unknown12.47M
- Unknown7.46M
- Unknown4.32M
- Unknown4.06M
- Unknown4.02M
- Unknown3.50M
- Unknown2.58M
- Unknown1.96M
- Unknown1.85M
- Unknown1.63M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
PHAT launches Phase 3 study for VOQUEZNA in GERD
Phathom Pharmaceuticals has begun a Phase 3 trial of VOQUEZNA, a drug aimed at treating non‑erosive gastro‑esophageal reflux disease on an as‑needed basis. The study is a critical step toward regulatory approval and could expand the company’s product portfolio. The move follows earlier development phases and may influence investor perception of the company’s growth prospects.
PHAT launches Phase 3 study for VOQUEZNA in GERD. Phathom Pharmaceuticals has begun a Phase 3 trial of VOQUEZNA, a drug aimed at treating non‑erosive gastro‑esophageal reflux disease on an as‑needed basis. The study is a critical step toward regulatory approval and could expand the company’s product portfolio. The move follows earlier development phases and may influence investor perception of the company’s growth prospects.